TY - JOUR
T1 - Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status
T2 - the Mayo Clinic Study of Aging
AU - Krell-Roesch, Janina
AU - Vassilaki, Maria
AU - Mielke, Michelle M.
AU - Kremers, Walter K.
AU - Lowe, Val J.
AU - Vemuri, Prashanthi
AU - Machulda, Mary M.
AU - Christianson, Teresa J.
AU - Syrjanen, Jeremy A.
AU - Stokin, Gorazd B.
AU - Butler, Lesley M.
AU - Traber, Martin
AU - Jack, Clifford R.
AU - Knopman, David S.
AU - Roberts, Rosebud O.
AU - Petersen, Ronald C.
AU - Geda, Yonas E.
N1 - Funding Information:
Support for this research was provided by NIH grants: National Institute on Aging (R01 AG057708; U01 AG006786; P50 AG016574; K01 AG028573; R01 AG034676; R01 AG041851; R01 AG011378) and National Institute of Mental Health (K01 MH068351). This project was also supported by F. Hoffman-La Roche, the Robert Wood Johnson Foundation, the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer’s Disease Research Program, the GHR Foundation, the Mayo Foundation for Medical Education and Research, Project LQ1605 from the National Program of Sustainability II (MEYS CR), the Edli Foundation, and the Arizona Alzheimer’s Consortium.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical β-amyloid (Aβ) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging to examine the frequency of NPS among cognitively unimpaired (CU) and mild cognitive impairment (MCI) participants who either have normal (A−) or abnormal (A+) Aβ deposition. We also investigated whether combined presence of MCI and amyloid positivity (MCI/A+) is associated with greater odds of having NPS as compared to CU/A− (defined as reference group). Participants were 1627 CU and MCI individuals aged ≥ 50 years (54% males; median age 73 years). All participants underwent NPS assessment (Neuropsychiatric Inventory Questionnaire (NPI-Q); Beck Depression Inventory II (BDI-II); Beck Anxiety Inventory (BAI)) and 11 C-PiB-PET. Participants with an SUVR > 1.42 were classified as A+. We conducted multivariable logistic regression analyses adjusted for age, sex, education, and APOE ε4 genotype status. The sample included 997 CU/A−, 446 CU/A+, 78 MCI/A−, and 106 MCI/A+ persons. For most NPS, the highest frequency of NPS was found in MCI/A+ and the lowest in CU/A−. The odds ratios of having NPS, depression (BDI ≥ 13), or anxiety (BAI ≥ 8, ≥ 10) were consistently highest for MCI/A+ participants. In conclusion, MCI with Aβ burden of the brain is associated with an increased risk of having NPS as compared to MCI without Aβ burden. This implies that the underlying Alzheimer’s disease biology (i.e., cerebral Aβ amyloidosis) may drive both cognitive and psychiatric symptoms.
AB - Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical β-amyloid (Aβ) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging to examine the frequency of NPS among cognitively unimpaired (CU) and mild cognitive impairment (MCI) participants who either have normal (A−) or abnormal (A+) Aβ deposition. We also investigated whether combined presence of MCI and amyloid positivity (MCI/A+) is associated with greater odds of having NPS as compared to CU/A− (defined as reference group). Participants were 1627 CU and MCI individuals aged ≥ 50 years (54% males; median age 73 years). All participants underwent NPS assessment (Neuropsychiatric Inventory Questionnaire (NPI-Q); Beck Depression Inventory II (BDI-II); Beck Anxiety Inventory (BAI)) and 11 C-PiB-PET. Participants with an SUVR > 1.42 were classified as A+. We conducted multivariable logistic regression analyses adjusted for age, sex, education, and APOE ε4 genotype status. The sample included 997 CU/A−, 446 CU/A+, 78 MCI/A−, and 106 MCI/A+ persons. For most NPS, the highest frequency of NPS was found in MCI/A+ and the lowest in CU/A−. The odds ratios of having NPS, depression (BDI ≥ 13), or anxiety (BAI ≥ 8, ≥ 10) were consistently highest for MCI/A+ participants. In conclusion, MCI with Aβ burden of the brain is associated with an increased risk of having NPS as compared to MCI without Aβ burden. This implies that the underlying Alzheimer’s disease biology (i.e., cerebral Aβ amyloidosis) may drive both cognitive and psychiatric symptoms.
UR - http://www.scopus.com/inward/record.url?scp=85063624858&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063624858&partnerID=8YFLogxK
U2 - 10.1038/s41398-019-0456-z
DO - 10.1038/s41398-019-0456-z
M3 - Article
C2 - 30923322
AN - SCOPUS:85063624858
SN - 2158-3188
VL - 9
JO - Translational psychiatry
JF - Translational psychiatry
IS - 1
M1 - 123
ER -